BUFFALO, NY--(Marketwire - October 18, 2007) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (BOST: CBLI) today announced that it has completed Good Manufacturing Practices compliant (cGMP) manufacturing of Protectan CBLB502. Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs, stated, “We are pleased to report that the technology transfer to our manufacturing partner, SynCo Bio Partners, and production of the first cGMP batch of Protectan CBLB502 were both completed on schedule. The yields from the process and the purity of the final product exceeded our expectations. We were able to develop a complicated, high-yield manufacturing process for CBLB502 due to the excellent work of our sub-contractors at SynCo Bio Partners and our in-house team, which was able to prototype the process and resolve multiple challenges during industrial development together with our consultants.”
